[Imipenem: 30-year experience in therapy].
S V
SV
Sidorenko
I V
IV
Partina
V A
VA
Ageevets
D000150:Acinetobacter / Q000187:drug effects / Q000254:growth & development; D000900:Anti-Bacterial Agents / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D004338:Drug Combinations; D004926:Escherichia coli / Q000187:drug effects / Q000254:growth & development; D015870:Gene Expression; D016905:Gram-Negative Bacterial Infections / Q000188:drug therapy* / Q000382:microbiology; D006801:Humans; D015378:Imipenem / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use*; D011550:Pseudomonas aeruginosa / Q000187:drug effects / Q000254:growth & development; D018440:beta-Lactam Resistance / Q000235:genetics*; D001618:beta-Lactamases / Q000235:genetics / Q000378:metabolism
D000900:Anti-Bacterial Agents; D004338:Drug Combinations; D015378:Imipenem; D001618:beta-Lactamases